Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Rankning i aktier
#4847
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Aktiekurs
$2.55
Marknadsvärde
$3.05B
Förändring (1 dag)
3.33%
Förändring (1 år)
-11.84%
Land
CN
Handel Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategori
Healthcare
Vinst för Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Vinst i Jun 2026 TTM: $450.70M
Enligt de senaste finansiella rapporterna från Jilin Aodong Pharmaceutical Group Co., Ltd. är företagets nuvarande vinst $450.70M. År 2023 hade företaget en vinst på $211.93M, en minskning jämfört med vinsten år 2022 som var $249.47M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Jilin Aodong Pharmaceutical Group Co., Ltd. från 2000 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $450.70M | 116.23% |
| 2024 | $208.44M | -1.65% |
| 2023 | $211.93M | -15.05% |
| 2022 | $249.47M | -10.25% |
| 2021 | $277.96M | 5.78% |
| 2020 | $262.76M | 23.65% |
| 2019 | $212.51M | 47.80% |
| 2018 | $143.78M | -51.61% |
| 2017 | $297.11M | 18.54% |
| 2016 | $250.63M | -39.05% |
| 2015 | $411.21M | 71.49% |
| 2014 | $239.79M | 22.14% |
| 2013 | $196.32M | 79.35% |
| 2012 | $109.46M | -71.97% |
| 2011 | $390.52M | 99.92% |
| 2010 | $195.34M | -5.51% |
| 2009 | $206.72M | 55.20% |
| 2008 | $133.20M | -52.18% |
| 2007 | $278.56M | 315.81% |
| 2006 | $66.99M | 289.48% |
| 2005 | $17.20M | -21.22% |
| 2004 | $21.83M | 20.73% |
| 2003 | $18.09M | 43.68% |
| 2002 | $12.59M | 67.81% |
| 2001 | $7.50M | -36.78% |
| 2000 | $11.87M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 291.51% |
IN
|
